Fact Source: Financial Supervisory Service DART / 2025-05-22
Disclosure Type: Decision on Corporate Division (Report on Important Matters / Exchange Disclosure Obligation)
💡 3-Second Summary SAMSUNG BIOLOGICS is executing a spin-off (equity split) to create a new entity dedicated to managing biosimilar subsidiaries and investing in new businesses. Current shareholders will receive shares of the new company proportionally based on their existing ownership.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Method of Division: A simple spin-off (demerger) pursuant to Articles 530-2 to 530-11 of the Korean Commercial Act. Current shareholders will be allocated shares of the newly established entity in proportion to their shareholding ratio as of the allotment base date.
- Structural Separation:
- Surviving Entity: SAMSUNG BIOLOGICS CO., LTD. (Remaining listed on the KOSPI Market, engaging in the CDMO business division).
- Newly Established Entity: Samsung Episholdings Co., Ltd. (Tentative name; scheduled for relisting on the KOSPI Market, focusing on managing subsidiaries including Samsung Bioepis Co., Ltd. and new investments).
- Split Ratio (Based on financial statements as of March 31, 2025):
- Surviving Entity: 0.6503913 (65.04%)
- Newly Established Entity: 0.3496087 (34.96%)
- Calculation Basis: New entity net asset (KRW 3,356,221,465,038) / Pre-split total net asset (KRW 9,599,937,538,001)
- Financial Details Post-Split (As of March 31, 2025):
- Surviving Entity (SAMSUNG BIOLOGICS): Total Assets KRW 9,986,729,911,728; Total Liabilities KRW 3,743,013,838,765; Total Equity KRW 6,243,716,072,963 (Capital Stock: KRW 115,727,377,500). Revenue of the most recent fiscal year: KRW 3,497,145,675,782.
- Newly Established Entity (Samsung Episholdings): Total Assets KRW 3,365,179,974,094; Total Liabilities KRW 8,958,509,056; Total Equity KRW 3,356,221,465,038 (Capital Stock: KRW 62,207,622,500). Revenue of the most recent fiscal year: None (-).
- Key Timeline:
- Board of Directors Resolution Date: 2025-05-22 (All 4 outside directors attended)
- Shareholder Confirmation Base Date: 2025-07-29
- General Meeting of Shareholders: 2025-09-16
- Trading Suspension Period: 2025-09-29 to 2025-10-28
- Allotment Base Date for New Shares: 2025-09-30
- Spin-off Date & Scheduled Registration Date: 2025-10-01
- Listing Date of New Shares (Relisting): 2025-10-29
- Key Terms & Conditions:
- Joint Liability: The surviving entity and the new entity will remain jointly and severally liable for the obligations incurred by the company prior to the demerger. Due to this joint liability mechanism protecting creditors and shareholders, creditor objection procedures and appraisal rights for dissenting shareholders are not applicable.
- Fractional Shares: Fractional shares less than 1 share will be paid out in cash based on the closing price on the initial relisting day. The new entity will acquire these fractional shares as treasury stock.
- Future Plans: The new entity plans to establish a new subsidiary focusing on bio-related new businesses before the relisting application date. Furthermore, the new entity intends to ensure that its subsidiary, Samsung Bioepis Co., Ltd., will not list its shares on the Korea Exchange or similar domestic/overseas stock markets for 5 years from the new entity’s registration date.
- Employment Transfer: The new entity will fully assume the employment contracts and related legal relationships of all employees working in the spin-off division as of the demerger date.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This corporate restructuring represents a major structural change in the company’s long-term fundamental rather than a short-term transitional event.
The primary highlight is the stated objective of “eliminating potential conflict of interest concerns.” SAMSUNG BIOLOGICS, despite implementing strict operational firewalls, has faced concerns from global clients regarding conflicts of interest due to owning a biosimilar development subsidiary. By spinning off this business, SAMSUNG BIOLOGICS may solidify its position as a pure-play CDMO specialist, potentially attracting more secure global contracts.
The newly formed Samsung Episholdings will operate as a holding company under the Fair Trade Act, overseeing the biosimilar business and seeking new bio-related engines. Notably, the pledge not to list Samsung Bioepis for the next 5 years serves as a protective barrier against double-counting discounts, which typically hurts holding company valuations in Korea.
However, investors must note that trading will be suspended for a month from September 29 to October 28, 2025. This transition may create short-term portfolio volatility as the market prepares to evaluate two distinctly focused listed entities post-demerger.
📝 Editor’s Comment (by K-STOCK Editor)
SAMSUNG BIOLOGICS has finally regularized the market rumors regarding its split. Opting for a spin-off rather than a carve-out shows a clear intention to mitigate severe retail investor backlash, as shareholders maintain proportional ownership in both companies.
However, a serious approach is required. The split introduces a month-long trading suspension period, during which investors’ capital will be completely locked up. While the 5-year non-listing commitment for Bioepis safeguards against immediate holding company double-counting discounts, the new entity’s plan to aggressively establish a new subsidiary before relisting implies capital requirements and deployment risks that are yet to be fully detailed. Investors should look past the structural layout and meticulously evaluate how both the pure-play CDMO entity and the new sub-holding vehicle will be distinctively valued when trading resumes.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
